Improve Walking Performance Research Articles

Extended Capture Point and Optimization-based Control for Quadrupedal Robot Walking on Dynamic Rigid Surfaces

Stabilizing legged robot locomotion on a dynamic rigid surface (DRS) (i.e., rigid surface that moves in the inertial frame) is a complex planning and control problem. The complexity arises due to the hybrid nonlinear walking dynamics subject to explicitly time-varying holonomic constraints caused by the surface movement. The first main contribution of this study is the extension of the capture point from walking on a static surface to locomotion on a DRS as well as the use of the resulting capture point for online motion planning. The second main contribution is a quadratic-programming (QP) based feedback controller design that explicitly considers the DRS movement. The stability and robustness of the proposed control approach are validated through simulations of a quadrupedal robot walking on a DRS with a rocking motion. The simulation results also demonstrate the improved walking performance compared with our previous approach based on offline planning and input-output linearizing control that does not explicitly guarantee the feasibility of ground contact constraints.

Data-Driven Prediction of Freezing of Gait Events From Stepping Data.

Freezing of gait (FoG) is typically a symptom of advanced Parkinson's disease (PD) that negatively influences the quality of life and is often resistant to pharmacological interventions. Novel treatment options that make use of auditory or sensory cues might be optimized by prediction of freezing events. These predictions might help to trigger external sensory cues—shown to improve walking performance—when behavior is changed in a manner indicative of an impending freeze (i.e., when the user needs it the most), rather than delivering cue information continuously. A data-driven approach is proposed for predicting freezing events using Random Forrest (RF), Neural Network (NN), and Naive Bayes (NB) classifiers. Vertical forces, sampled at 100 Hz from a force platform were collected from 9 PD subjects as they stepped in place until they at least had one freezing episode or for 90 s. The F1 scores of RF/NN/NB algorithms were computed for different IL (input to the machine learning algorithm), and GL (how early the freezing event is predicted). A significant negative correlation between the F1 scores and GL, highlighting the difficulty of early detection is found. The IL that maximized the F1 score is approximately equal to 1.13 s. This indicates that the physiological (and therefore neurological) changes leading to freezing take effect at-least one step before the freezing incident. Our algorithm has the potential to support the development of devices to detect and then potentially prevent freezing events in people with Parkinson's which might occur if left uncorrected.

압박웨어 착용강도가 보행에 미치는 영향 : 트레드밀 보행과 지상 보행의 비교

This study is a behavioral study that examines how gait performance and gait variability can vary depending on the strength of compression wear in two gait exercises. Although commercially available compression wear differs in the area of compression and design, there are few specific research cases on the effect of compression wear on the gait. In particular, it was predicted that clarifying the difference in performance according to the intensity of compression in ground walking and treadmill walking could help to evaluate the effectiveness of compression wear in walking exercises. Accordingly, the purpose of this study was to investigate whether the kinematic patterns of gait vary depending on the type of compression (no compression, low compression, high pressure compression), and second, between the conditions of walking (treadmill, ground) and the compression type. Interactions were assessed. As a result of the study, overall, wearing high pressure compression garment when walking on a treadmill partially reduced walking variability, and the effect of improving walking performance when walking on the ground was not clear. When there was no compression, the walking speed increased, but when it was related to the movement of the distal foot, the compression induced a greater range of motion. Therefore, it is judged that it is effective to use high pressure compression garment differently for the purpose of improving stability and performance in treadmill walking and ground walking.

Combined effect of repetitive transcranial magnetic stimulation and treadmill training on walking endurance and balance in people with Parkinson's disease

Objective: Reduced walking endurance and balance is common among patients with Parkinson's disease (PD). Treadmill training and transcranial magnetic stimulation (rTMS) have been shown to be effective in improving walking performance in patients with PD, but effects were modest and short-lived. This study aimed to examine the long-term effect of combined rTMS and treadmill training on walking endurance and balance performance in patients with PD.

Rapid reduction in plaque inflammation by sonodynamic therapy inpatients with symptomatic femoropopliteal peripheral artery disease:A randomized controlled trial

BackgroundInflammation is actively involved in the clinical manifestation of peripheral artery disease (PAD). Sonodynamic therapy (SDT), a novel non-invasive, plaque-based, macrophage-targeted anti-inflammatory regimen for atherosclerosis has the potential to improve walking performance by reducing plaque inflammation. MethodsThis phase-2, randomized, sham-controlled, double-blind clinical trial enrolled 32 participants with symptomatic femoropopliteal PAD. The primary outcome was the 30-day change in the target-to-background ratio (TBR) within the most diseased segment (MDS) of the femoropopliteal artery assessed through positron emission tomography/computed tomography (PET/CT). The secondary outcomes were changes in walking performance, limb perfusion, lesional morphology and quality of life measurements. ResultsThe mean age was 64.7 years and 63% were male. Thirty-one completed follow-up. SDT significantly decreased the MDS TBR by 0.53 (95% CI, −0.70 to −0.36, P < 0.001) compared with control. Furthermore, SDT increased peak walking time by 118.6 s (95% CI, 74.3 to 163.0, P < 0.001), increased ankle-brachial index by 0.11 (95% CI, 0.07 to 0.14, P < 0.001), decreased lesional diameter and area stenosis by 7.2% (95% CI, −8.6 to −4.5, P < 0.001) and 9.6% (95% CI, −24.5 to −5.3, P = 0.005), respectively, and increased the walking speed score of the Walking Impairment Questionnaire by 16.1 (95% CI, 2.6 to 29.5, P = 0.021) and the physical functioning score of the 36-item Short-Form Health Survey by 10.0 (95% CI, 5.0 to 20.0, P = 0.003) compared with control. These improvements were maintained in the SDT group up to 6-month. ConclusionsSDT rapidly reduced plaque inflammation and improved walking performance among patients with symptomatic PAD. Trial registrationClinical Trials NCT03457662.

Skeletal Muscle Pathology in Peripheral Artery Disease: A Brief Review.

This brief review summarizes current evidence regarding lower extremity peripheral artery disease (PAD) and lower extremity skeletal muscle pathology. Lower extremity ischemia is associated with reduced calf skeletal muscle area and increased calf muscle fat infiltration and fibrosis on computed tomography or magnetic resonance imaging. Even within the same individual, the leg with more severe ischemia has more adverse calf muscle characteristics than the leg with less severe ischemia. More adverse computed tomography-measured calf muscle characteristics, such as reduced calf muscle density, are associated with higher rates of mobility loss in people with PAD. Calf muscle in people with PAD may also have reduced mitochondrial activity compared with those without PAD, although evidence is inconsistent. Muscle biopsy document increased oxidative stress in PAD. Reduced calf muscle perfusion, impaired mitochondrial activity, and smaller myofibers are associated with greater walking impairment in PAD. Preliminary evidence suggests that calf muscle pathology in PAD may be reversible. In a small uncontrolled trial, revascularization improved both the ankle-brachial index and mitochondrial activity, measured by calf muscle phosphocreatine recovery time. A pilot clinical trial showed that cocoa flavanols increased measures of myofiber health, mitochondrial activity, and capillary density while simultaneously improving 6-minute walk distance in PAD. Calf muscle pathological changes are associated with impaired walking performance in people with PAD, and interventions that both increase calf perfusion and improve calf muscle health are promising therapies to improve walking performance in PAD.

Day-to-Day Variability of Walking Performance Measures in Individuals Poststroke and Individuals With Parkinson Disease

Improvement of walking performance is a primary goal for individuals poststroke or with Parkinson disease (PD) who receive physical therapy. More data about day-to-day variability of walking performance are critical for determining if changes in performance have occurred. Baseline assessments were utilized from an ongoing, observational, prospective cohort study including 84 individuals poststroke (n = 37) or with PD (n = 47) receiving outpatient physical therapy services to improve mobility. Participants wore step activity monitors for up to 7 days to measure walking performance (steps per day, walking duration, maximum 30-minute output, and peak activity index) in daily life. Correlation analyses evaluated relationships between both capacity and performance measures as well as the relationships between mean performance variables and day-to-day variability. Regression analyses explored factors that contribute to variability in day-to-day performance variables. Mean steps per day for participants poststroke (5376 ± 2804) and with PD (8149 ± 4490) were consistent with previously reported cohorts. Greater amounts of walking were related to more day-to-day variability, with moderate correlations found between the mean and day-to-day variability of each performance measure, regardless of medical diagnosis or walking speed. Day-to-day variability is large (upwards of 50% of the mean), with the amount of walking performance serving as the primary predictor of day-to-day variability in walking performance. The results of this study elucidate the factors that are related to and predict day-to-day variability of performance. Walking performance metrics should be evaluated over multiple days and greater variability should be anticipated with greater amounts of performance.Video Abstract available for more insights from the authors (see the Video, Supplemental Digital Content 1, available at: http://links.lww.com/JNPT/A319).

The Effect of Arterial Disease Level on Outcomes of Supervised Exercise Therapy for Intermittent Claudication: A Prospective Cohort Study.

To assess whether level of arterial obstruction determines the effectiveness of SET in patients with IC. Guidelines advocate SET before invasive treatment for IC, but early revascularization remains widespread, especially in patients with aortoiliac disease. Patients were recruited from 10 Dutch centers between October 2017 and October 2018. Participants received SET first, followed by endovascular or open revascularization in case of insufficient effect. They were grouped according to level of stenosis (aortoiliac, femoropopliteal, multilevel, or rest group with no significant stenosis). Changes from baseline walking performance (maximal and functional walking distance on a treadmill test, 6-minute walk test) and vascular quality of life questionnaire-6 at 3 and 6 months were compared, after multivariate adjustment for possible confounders. Freedom from revascularization was estimated with Kaplan-Meier analysis. Some 267 patients were eligible for analysis (aortoiliac n = 70, 26%; femoropopliteal n = 115, 43%; multilevel n = 69, 26%; rest n = 13, 5%). No between group differences in walking performance or vascular quality of life questionnaire-6 were found. Mean improvement in maximal walking distance after 6 months was 439 m [99% confidence interval (CI) 297-581], 466 m (99% CI 359-574), 353 m (99% CI 210-496), and 403 m (99% CI 58-749), respectively (P = 0.40). Freedom from intervention was 73.9% for aortoiliac disease and 88.6% for femoropopliteal disease (hazard ratio 2.46, 99% CI 0.96 - 6.30, P = 0.013). Short-term effectiveness of SET for IC is not determined by the location of stenosis. Although aortoiliac disease patients improved walking performance and health-related quality of life similarly compared to other arterial disease level groups, they underwent revascularization more often.

Closing the Loop on Exoskeleton Motor Controllers: Benefits of Regression-Based Open-Loop Control.

Lower-limb exoskeletons are widely researched to improve walking performance and mobility. Low-level sensor-less exoskeleton motor control is attractive for consumer applications due to reduced device complexity and cost, but complex and variable transmission system configurations make the development of effective open-loop motor controllers that are responsive to user input challenging. The objective of this study was to develop and validate an open-loop motor control framework resulting in similar or greater performance vs. closed-loop torque control. We used generalized linear regression to develop two open-loop controllers by modeling motor current during exoskeleton-assisted walking; a "complex" model used desired torque and estimated ankle angular velocity as inputs, while a "simple" model used desired torque alone. Five participants walked at 1.0-1.3 m/s on a treadmill with closed-loop and both open-loop controllers providing ankle exoskeleton assistance. Both open-loop current controllers had similar root-mean-squared torque tracking error (p=0.23) compared to the closed-loop torque-feedback controller. Both open-loop controllers had improved relative average torque production (p<0.001 complex, p=0.022 simple), lower power consumption (p<0.001 for both), and reduced operating noise (p=0.002 complex, p<0.001 simple) over the closed-loop controller. New control models developed for a different ankle exoskeleton configuration showed similar improvements (lower torque error, greater average and peak torque production, lower power consumption) over closed-loop control during over-ground walking. These results demonstrate that our framework can produce open-loop motor controllers that match closed-loop control performance during exoskeleton operation.

Curcumagalactomannoside/Glucosamine Combination Improved Joint Health Among Osteoarthritic Subjects as Compared to Chondroitin Sulfate/Glucosamine: Double-Blinded, Randomized Controlled Study.

Objective: A combination of curcumagalactomannosides (CGM) (400 mg) with glucosamine hydrochloride (GLN) (500 mg) was evaluated against a standard dietary supplement combination chondroitin sulfate (CHN) (415 mg)/GLN (500 mg) for their effectiveness in alleviating the pain and symptoms among osteoarthritic subjects. Design: Randomized, double-blinded and active-controlled study. Settings/Location: The study was conducted in a hospital-based research center in Vadodara, Gujarat, India. Subjects: Eighty subjects (38 males and 42 females), with confirmed osteoarthritis (OA) (Class I-III), were randomized into two parallel groups designated as Group I (CGM-GLN) and Group II (CHN-GLN). Interventions: All the study subjects were supplemented with their corresponding intervention capsules (ether CGM along with GLN or CHN along with GLN), as a single oral dose twice a day, once in the morning 10-15 min before breakfast and again in the evening before dinner, for 84 days. Outcome measures: A validated treadmill uphill walking protocol was used for the study, and the efficiency of supplementation was evaluated using visual analogue scale (VAS) score, Karnofsky Performance Scale (KPS) score, and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire at the baseline, 28th, and 84th day following the treatment. Mechanism of action of CGM-GLN combination was analyzed by measuring the levels of serum inflammatory markers interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and soluble vascular cell adhesion molecule-1 (sVCAM) at the baseline and 84th day. Results: CGM-GLN was found to offer significant beneficial effects to pain, stiffness, and physical function of OA subjects compared with CHN-GLN, which was evident from the improvement in walking performance, VAS score, KPS score, and WOMAC score. The efficiency of CGM-GLN was almost double compared with the CHN-GLN by the end of the study (84th day). A significant reduction of inflammatory serum marker levels was observed among CGM-GLN subjects compared with CHN-GLN subjects. Compared with the baseline, CGM-GLN produced 54.52%, 59.08%, and 22.03% reduction in IL-1β, IL-6, and sVCAM levels, respectively. Whereas CHN-GLN group of subjects expressed only 23.17%, 21.38%, and 6.82% reduction in IL-1β, IL-6, and sVCAM levels, respectively. Conclusions: In conclusion, the present study demonstrated the potential benefits of CGM-GLN supplements in alleviating the symptoms and function of OA subjects compared with the standard CHN-GLN treatment. The augmented efficacy of CGM-GLN combination could be attributed to the enhanced anti-inflammatory effect of CGM.

Falling risk in patients with end-stage knee osteoarthritis.

Although 25% of patients with end-stage knee osteoarthritis (OA) have reported a fall, there is limited information about risk factors for falling in patients awaiting total knee arthroplasty (TKA). The purpose of this study was to identify clinical and functional measures related to fall risk. A total of 259 participants awaiting TKA for OA participated in this secondary cross-sectional study. Participants were divided into fallers and non-fallers based on falling history in the prior 6months. Clinical measures (hip and knee pain, neck and low back pain (LBP), knee range of motion, and quadriceps strength) and functional measures (six-minute walk test (6MWT), timed up and go test, and Knee Injury and Osteoarthritis Outcome Score (KOOS)) were assessed in patients 2-4weeks prior to TKA. Independent t tests were used to examine differences between groups. Odds ratio was calculated to identify clinical risk factors for falling. Of all participants, 47 (18%) reported a fall in the previous 6months. Fallers had 30% greater LBP (3.0 ± 2.5 vs. 2.1 ± 2.6; p = 0.025). Fallers walked 12% shorter distance in the 6MWT than non-fallers (378 ± 100 vs. 422 ± 105m; p = 0.010). For every 1-point increase in LBP on a 0-10 scale, there was a 14% greater risk of falling (p = 0.028). For every 10-m increase in 6MWT, there was a 3.8% reduction in fall risk (p = 0.011). Greater LBP and worse walking endurance are associated with falls in individuals with end-stage OA. Future studies should determine if interventions that reduce LBP and improve walking performance also reduce the chance of falling.

Effect of hippotherapy on walking performance and gait parameters in people with multiple sclerosis

BackgroundWalking dysfunction is one of the most common symptoms of multiple sclerosis (MS). ObjectiveTo evaluate the effects of an 8-week hippotherapy intervention on walking performance and spatiotemporal gait parameters in people with relapsing-remitting MS; and to examine whether the effects of hippotherapy on walking performance are mediated by changes in spatiotemporal gait parameters. MethodsParticipants were assigned into a hippotherapy intervention group (n = 17) or a control group (n = 16). The intervention included 16 sessions of 30-minutes of hippotherapy conducted twice a week. Participants underwent the 25-foot walk test (T25FW) and 6-minute walk test (6MWT), as primary outcomes, and spatiotemporal gait evaluation using GaitRite system, as secondary outcomes, before and after intervention. The data were examined using mixed model ANOVA with Bonferroni post hoc. Mediation analysis was conducted as per Baron and Kenny's criteria. ResultsCompared with control, the intervention group significantly increased 6MWT distance (+9.70%, p<0.001) and decreased T25FW time (-15.86%, p<0.001).Regarding spatiotemporal gait parameters, the intervention group exhibited significantly greater improvements in most variables (Δ% from 3.66 and 41.43%; all p<0.005) than control. Only balance time (p = 0.043), stance time (p = 0.031), and absolute (p = 0.004) and relative (p = 0.017) double support time were identified as significant mediators of the effects of hippotherapy on walking performance evaluated by T25FW. There was no significant mediator for 6MWT (all p>0.05). ConclusionHippotherapy improved walking performance and spatiotemporal gait parameters in people with relapsing-remitting MS, and changes in walking performance, evaluated by T25FW, were partially driven by reduction in stance time and double support time and increase in balance time. Hippotherapy may be a useful complimentary treatment approach for improving walking in people with MS.

Development of quadruped walking robot with spherical shell: improvement of climbing over a step

We have proposed and developed a new quadruped walking robot with a spherical shell, called “QRoSS”. QRoSS is a transformable robot that can store its legs in the spherical shell. The shell not only absorbs external forces from all directions, but also improves mobile performance because of its round shape. In rescue operations at a disaster site, carrying robots into a site is dangerous for operators because doing so may result in a second accident. If QRoSS is used, instead of being carried in, robots are thrown in, making the operation safe and easy. We developed the QRoSS series and conducted basic experiments to verify performance, which includes landing, rising and walking through a series of movements. This paper reports details of a mechanical design to improve walking performance and development of the QRoSS V prototype model. We discuss the rising operation and performance of climbing over a high vertical step.

Heat therapy reduces blood pressure and circulating endothelin‐1 levels, but does not improve walking performance or vascular function in patients with symptomatic peripheral artery disease

INTRODUCTIONPatients with peripheral artery disease (PAD) are at a heightened risk of cardiovascular events and have markedly reduced vascular function and exercise tolerance. Heat therapy (HT) has emerged as a practical treatment to improve cardiovascular health in young individuals as well in patients with overt cardiovascular disease. We recently reported that a single 90 min session of HT applied to the legs of patients with PAD using water‐circulating trousers increases popliteal artery blood flow and reduces blood pressure and the circulating levels of the potent endogenous vasoconstrictor endothelin‐1 (ET‐1). The objective of the present study was to test the hypothesis that the repeated exposure to leg HT would lower blood pressure and ET‐1 levels and improve walking performance and conduit artery and cutaneous vascular function in patients with symptomatic PAD.METHODSThirty‐two patients with symptomatic PAD (Age: 68± 8 years; Ankle‐brachial index: 0.67 ± 0.1) were assigned using a balanced randomized design to undergo 90 min of HT (48°C) or a thermoneutral treatment (33°C) 3 times per week for 6 consecutive weeks. The following outcomes were assessed at baseline and 3 and 6 weeks after the intervention: 1) resting ankle‐brachial index, 2) post‐occlusive reactive hyperemia in the popliteal artery (phase contrast magnetic resonance imaging), 3) leg cutaneous thermal hyperemia (laser Doppler flowmetry), 4) resting blood pressure every 5 min for 70 min, 5) 6‐min walk distance and 6) serum levels of ET‐1 and total nitrate (NOx).RESULTSParticipants completed 17.7 ± 0.6 treatment sessions, resulting in a compliance rate of 98.7%. In the group exposed to HT, systolic blood pressure (SBP) decreased from baseline by ~3 mmHg at 6 weeks, while in the control group SBP increased by ~1 mmHg. A significant group by time interaction was observed for the changes in SBP from baseline to 6 weeks (p=0.0049) with significant group differences at 20 min (Change in SBP: Control: 6.27 ± 15.5 vs. HT: −7.60 ± 13.6 mmHg, p=0.015) and 60 min (Change in SBP: Control: 4.13 ± 15.1 vs. HT: −7.33 ± 13.7 mmHg, p=0.0386). Similarly, serum ET‐1 levels decreased by ~15% from baseline to week 6 following exposure to HT, while a ~6% increase in this parameter occurred in the control group (Change in ET‐1: Control: 0.16 ± 0.6 vs. HT: −0.30 ± 0.4 pg/mL, p=0.035 – one outlier removed). Resting ABI, diastolic BP, 6MWT distance, hyperemic peak flow and cutaneous thermal hyperemia were not different between groups.CONCLUSIONExposure to repeated HT reduces systolic blood pressure and ET‐1 levels in patients with symptomatic PAD. These findings indicate that HT may be a practical and accessible nonpharmacological tool to reduce cardiovascular risk in PAD patients.Support or Funding InformationAmerican Heart Association Scientist Development grant (16SDG27600003).

Meet the First Author.

Meet the First Author.

In This Issue

In This Issue

Cocoa might improve walking performance in PAD.

Cocoa might improve walking performance in PAD.

Effects of bodyweight support and guidance force on muscle activation during Locomat walking in people with stroke: a cross-sectional study

BackgroundLocomat is a robotic exoskeleton providing guidance force and bodyweight support to facilitate intensive walking training for people with stroke. Although the Locomat has been reported to be effective in improving walking performance, the effects of training parameters on the neuromuscular control remain unclear. This study aimed to compare the muscle activities between Locomat walking and treadmill walking at a normal speed, as well as to investigate the effects of varying bodyweight support and guidance force on muscle activation patterns during Locomat walking in people with stroke.MethodsA cross-sectional study design was employed. Participants first performed an unrestrained walking on a treadmill and then walked in the Locomat with different levels of bodyweight support (30% or 50%) and guidance force (40% or 70%) at the same speed (1.2 m/s). Surface electromyography (sEMG) of seven muscles of the affected leg was recorded. The sEMG envelope was time-normalised and averaged over gait cycles. Mean sEMG amplitude was then calculated by normalising the sEMG amplitude with respect to the peak amplitude during treadmill walking for statistical analysis. A series of Non-parametric test and post hoc analysis were performed with a significance level of 0.05.ResultsFourteen participants with stroke were recruited at the Yangzhi Affiliated Rehabilitation Hospital of Tongji University (female n = 1; mean age 46.1 ± 11.1 years). Only the mean sEMG amplitude of vastus medialis oblique during Locomat walking (50% bodyweight support and 70% guidance force) was significantly lower than that during treadmill walking. Reducing both bodyweight and guidance increased muscle activity of gluteus medius and tibialis anterior. Activity of vastus medialis oblique muscle increased as bodyweight support reduced, while that of rectus femoris increased as guidance force decreased.ConclusionsThe effects of Locomat on reducing muscle activity in people with stroke were minimized when walking at a normal speed. Reducing bodyweight support and guidance force increased the activity of specific muscles during Locomat walking. Effects of bodyweight support, guidance force and speed should be taken into account when developing individualized Locomat training protocols for clients with stroke.

Physical activity and peak oxygen consumption are associated with walking in multiple sclerosis

IntroductionMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with a prevalence of nearly 1 million adults in the United States. MS results in declines in physical activity and peak oxygen consumption that might be independently associated with declines in walking performance. Therefore our purpose was to evaluate the association between physical activity and peak oxygen consumption with walking performance in individuals with MS. MethodsFifty individuals with MS between the ages of 18–70 yrs. (Female: 38; 46 ± 12 yrs.; BMI: 28.5 ± 6.4; EDSS: 3.3 [IQR: 2.5–4]) performed a maximal incremental cycle test to assess peak oxygen consumption (VO2peak), and wore an accelerometer for one week to measure moderate-to-vigorous physical activity (MVPA). Subjects further completed a timed 25-foot walk test (T25FW) and 6-minute walk (6MW) to measure walking performance. ResultsMVPA and VO2peak were correlated with 6MW and T25FW (p < 0.05). When combined in multivariate regression analyses, VO2peak and MVPA were both significant contributors of T25FW speed and 6MW, but after controlling for sex and age, MVPA was the only significant contributor (β = 0.32 and β = 0.44, respectively). ConclusionBoth higher MVPA and VO2peak were associated with better walking performance and in a combined model physical activity, but not peak oxygen consumption, remained an independent contributor to walking performance in individuals with MS. These results suggest that improving MVPA is a potential target for interventions to improve walking performance in persons with MS.

Efficacy and safety of Kinezia (fampridine) in the complex therapy of multiple sclerosis

To analyze the efficacy and safety of fampridine** (Valenta Pharm, Russia) in the complex therapy of multiple sclerosis (MS). One hundred and twenty-six patients with MS were double blind randomized to receive fampridine (n=60) or placebo (n=66). Fampridine was administered in prolonged-release form (film-coated tablets, 10 mg) at a dose of 10 mg (1 tablet) 2 times a day, for 24 weeks. The placebo group was treated in the same way. From the 12th week, all patients in the placebo group were transferred to therapy with fampridine, 10 mg 2 times a day, for another 12 weeks. Concomitant standard therapy for MS was allowed in both groups (concomitant disease-modifying medications and other treatment). The primary outcome in the study was the proportion of patients with reduced t25fw test time (determining walking speed on a 25-foot path) on at least two out of three visits compared to baseline. The mean change in Multiple Sclerosis Functional Composite (MSFC) scores from baseline was assessed at visits 4-7 (8-24 weeks). The proportion of patients with reduced t25fw test time compared to the baseline level was 31.7% in the fampridine group, which is higher than in the placebo group - 3.0% (p<0.001). The overall result of the Multiple Sclerosis Functional Composite (MSFC) reflected a gradual improvement in the patient's condition during treatment period. The dynamics of MSFC result relative to the baseline level significantly differed (p<0.05) between the fampridine and placebo groups in favor of the fampridine group during all treatment periods. In the fampridine group, adverse events (AE) associated with disorders of the nervous system were more common: headache, dizziness, and coordination disorders. Fampridine improves walking performance in MS patients. The Russian product fampridine has demonstrated a favorable safety profile.